APE1 shRNA‐loaded cancer stem cell‐derived extracellular vesicles reverse Erlotinib resistance in non‐small cell lung cancer via the IL‐6/STAT3 signalling [PDF]
Clinical and Translational Medicine, 2022 Objective Apurinic endonuclease 1 (APE1) has been suggested as an oncogene of lung tumours and our bioinformatics analysis identified the association between Erlotinib resistance and interleukin‐6 (IL‐6).
Chun‐Han Tang +6 more
doaj +3 more sources
Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway [PDF]
Frontiers in Oncology, 2021 BackgroundErlotinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, demonstrated therapeutic efficacy against pancreatic cancer.
Huiting Xu +6 more
doaj +2 more sources
Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses [PDF]
Hereditas, 2020 Background Non-small cell lung cancer (NSCLC) is the major type of lung cancer with high morbidity and poor prognosis. Erlotinib, an inhibitor of epidermal growth factor receptor (EGFR), has been clinically applied for NSCLC treatment.
Huyue Zhou +5 more
doaj +2 more sources
The Role of ARL4C in Erlotinib Resistance: Activation of the Jak2/Stat 5/β-Catenin Signaling Pathway [PDF]
Frontiers in Oncology, 2020 Cancer patients who initially benefit from Erlotinib, a drug targeting EGFR path, eventually develop resistance to the drug. The underlying mechanism is largely unknown.
Jinrong Liao +10 more
doaj +2 more sources
Exosomal Transfer of lncRNA H19 Promotes Erlotinib Resistance in Non-Small Cell Lung Cancer via miR-615-3p/ATG7 Axis [PDF]
Cancer Management and Research, 2020 Rongtao Pan,1 Haiyan Zhou2 1Department of Oncology, Taishan Hospital of Shandong Province, Taian 271000, Shandong, People’s Republic of China; 2Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical ...
Pan R, Zhou H
doaj +2 more sources
Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase [PDF]
Cancer & Metabolism, 2020 Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant forms of cancer. Lack of effective treatment options and drug resistance contributes to the low survival among PDAC patients. In this study, we investigated the metabolic alterations in
Neha Sharma +4 more
doaj +2 more sources
Hexane Fraction of Adenophora triphylla var. japonica Root Extract Inhibits Angiogenesis and Endothelial Cell-Induced Erlotinib Resistance in Lung Cancer Cells [PDF]
MoleculesThe aim of this study was to investigate the anti-angiogenic effects of the hexane fraction of Adenophora triphylla var. japonica root extract (HAT) and its influence on the development of erlotinib resistance in human lung cancer cells.
Hyun-Ji Park +3 more
doaj +2 more sources
Molecular Oncology, 2015 Despite the role of epidermal growth factor receptor (EGFR) signaling in head and neck squamous cell carcinoma (HNSCC) development and progression, clinical trials involving EGFR tyrosine kinase inhibitors (TKIs) have yielded poor results in HNSCC ...
Aditya Stanam +4 more
doaj +2 more sources
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c‐Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma [PDF]
Thoracic Cancer, 2020 Background Calpain 1 (CAPN1) has been found to be a promoter of cancer progression. PTPN1 as a physiological target molecule of CAPN1 plays a dephosphorylated role on multiple receptor tyrosine kinases.
Yichuan Chen +3 more
doaj +2 more sources
Increased expression of miR‐641 contributes to erlotinib resistance in non‐small‐cell lung cancer cells by targeting NF1 [PDF]
Cancer Medicine, 2018 Epidermal growth receptor (EGFR)‐targeted tyrosine kinase inhibitors (TKIs) have emerged as first‐line drugs for advanced non‐small‐cell lung cancer (NSCLC) patients with EFGR mutations.
Juan Chen +4 more
doaj +2 more sources